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Introduction
The 'adult respiratory distress syndrome', or ARDS,
is a term used to describe the sudden onset of acute respira-
tory failure characterized by pulmonary edema arising from
increased lung permeability.1 By definition four essential
components should be present:  1) chest X-ray evidence of
bilateral infiltrates, 2) exclusion of heart failure, by a wedge
of less than 20 mm HG or  clinical examination, 3) underly-
ing disease and 4) severe hypoxemia with a PaO2 / FiO2
ratio of < 200.  ARDS is a physiologic syndrome, not a sin-
gle disease which results in a ventilation- perfusion (v/q)
mismatch within the lung due to areas of poor ventilation.
As a result of the progressive hypoxemia, pulmonary vascu-
lar resistance also rises and can lead to right ventricular fail-
ure.1,2
The clinical syndrome is a common pathway result-
ing from a wide variety of insults, which can be intra- or
extra-pulmonary.  Although it has been a well-known entity
since the 'shock-lung' patients seen in the Vietnam war in
1967, the mortality still remains high.3 Many therapeutic
modalities have been used, but no single treatment measure
has shown significant improvement in mortality. These
include recruitment maneuvers, prone positioning, high
PEEP, low tidal volumes, inverse ratio ventilation and
inhaled nitric oxide.4 
In the last few years, prostaglandins have been
experimentally used via inhalation, in order to improve per-
fusion selectively in the well ventilated areas of the lung.
This reduces the V/Q mismatch and shunt, hereby improv-
ing oxygenation.5 Blood is thus diverted from areas of col-
lapse to the well- ventilated ones.  Studies suggest that in
ARDS, inhalation of aerosolized PGE1 (a breakdown prod-
uct of arachidonic acid with vasodilating properties) and
nitric oxide (NO) in low concentrations equally improve
pulmonary vascular resistance and gas exchange. NO is
much more expensive and associated with several compli-
cations.  PGE1 has also shown reduction in cytokine medi-
ated alveolar cell injury. Previous studies indicated that
PGE1 disaggregates platelets and reduces local vasocon-
striction in the pulmonary circulation.6
Case Report
A 6 year old (FK), known case of acute lymphocyt-
ic leukemia (ALL) was admitted with cough for 1 week and
shortness of breath for 1 day prior to presentation. Informed
consent was obtained from the family. He was admitted
with a diagnosis of pneumonia based on chest X Ray find-
ings and clinical picture.  After two days he required intuba-
tion and ICU admission for progressive hypoxemia and
bilateral diffuse infiltrates on CXR, in keeping with ARDS.
He was sedated and relaxed for his worsening status requir-
ing maximal ventilatory support.  He was also started on
clarithromycin, Septran and meropenem.  On the fourth day,
when despite a ventilatory  support of 1.0 FiO2 and pressure
control ventilation with a peep of 15 cm H2O, his PaO2 did
not improve more than 49 mmHg  (Alveolar - arterial gradi-
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Table.  Arterial Blood gases before and after PGE1 nebulisation.
Day 10 Without PGE1
Ventilator
settings AM Arterial blood gas PM arterial blood gas
Pressure control 18 pH 7.31 pH  7.32
Respiratory Rate 35 PaCO2  65 PCO2  56
Peep 15 PaO2  49 PaO2  53
FiO2 1.0 HCO3  33 HCO3  30
Base excess 5 BE  3
Saturation 79% Saturation  84%
Day 11 First dose of PGE1 Three doses of PGE1 
Ventilator AM arterial blood gases PM blood gases
setting
Pressure control  16 pH  7.29 pH  7.22
Respiratory Rate 39 PaCO2  53  PaCO2  78
Peep 15 PaO2  103 PaO2  86
FiO2 1.0 HCO3  24 HCO3  32
BE -2 BE  3
Saturation  96% Saturation  93%
Day 12 5 doses of PGE1 8 doses of PGE1
Ventilator AM arterial blood gases PM arterial blood gases
settings
PC  16 pH  7.30 pH  7.3
RR  39 PaCO2  59 PaCO2  67
Peep 15 PaO2  61 PaO2  56
FiO2 1.0 HCO3  32 HCO3  35
BE  5 BE 7.5
Saturation  86% Saturation  85%
arterial gradient of 450 mmHg), he was placed in a
prone position7 for eight hours / day.  He was also started on
high dose IV methylprednisolone7,8 in accordance with
management of ARDS, on day 6.  However, his respiratory
acidosis and hypoxia continued.  His chest Xray continued
to show a diffuse ground glass appearance.
On day 10, Alprostadil (PGE1)9,10 was nebulised
over 30  minutes every six hours. The dose used was 5
mcgs. in  normal saline.  Over the next 12-24 hours a
marked improvement in oxygenation was seen on his arteri-
al blood gases (Table).  His A-a gradient improved, howev-
er, his CXR remained unchanged. No other parameter (pron-
ing, ventilatory support, antibiotics) was changed during the
therapy.  This improvement in PaO2 was not sustained and
drifted down once again, despite increasing the PGE1 neb-
ulisation frequency.  He died on day 13 of admission fol-
lowing a bradycardic arrest and worsening sepsis.
Discussion
Alprostadil (PGE1) is a product of the arachidonic
acid metabolism and causes vasodilation by increasing
camp.11 Intractable respiratory failure and hypoxemia lead-
ing to multi organ failure in ARDS patient remains a diffi-
cult to manage problem for most intensivists. It also pres-
ents a huge burden on health care costs. Although many
strategies have been proposed and research is ongoing for
finding remedies for this illness, no single therapy or
maneuver has improved outcome or mortality.  Inhaled
vasodilators that affect the pulmonary vasculature selective-
ly (i.e. only the perfusion of areas well ventilated) are
appealing adjuncts in many cardiopulmonary conditions
that require mechanical ventilation such as ARDS, COPD
and  Primary pulmonary hypertension.12 Inhaled nitric
oxide (NO) and aerosolized prostaglandins like  PGE1 offer
advantage of selective pulmonary vasodilation with mini-
mal systemic effects.13 Both agents decrease peak airway
pressures (PAP), pulmonary vascular resistance (PVR) and
in many cases improve oxygenation acutely; however, the
effect has not led to improved long-term outcomes.  Nitric
oxide, besides being expensive and not readily available,
has systemic side effects.14,15 Currently, their use remains
investigational and  no large randomised controlled trials
have been done to see the efficacy.
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